Geode Capital Management LLC increased its stake in Uniqure NV (NASDAQ:QURE) by 75.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,445 shares of the biotechnology company’s stock after purchasing an additional 15,295 shares during the period. Geode Capital Management LLC’s holdings in Uniqure were worth $1,021,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wells Fargo & Company MN lifted its holdings in shares of Uniqure by 24.2% in the 3rd quarter. Wells Fargo & Company MN now owns 17,829 shares of the biotechnology company’s stock worth $649,000 after purchasing an additional 3,472 shares during the last quarter. Federated Investors Inc. PA lifted its holdings in shares of Uniqure by 43.5% in the 3rd quarter. Federated Investors Inc. PA now owns 1,565,600 shares of the biotechnology company’s stock worth $56,972,000 after purchasing an additional 474,320 shares during the last quarter. Vanguard Group Inc lifted its holdings in shares of Uniqure by 4.1% in the 3rd quarter. Vanguard Group Inc now owns 101,992 shares of the biotechnology company’s stock worth $3,712,000 after purchasing an additional 3,992 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Uniqure by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 101,992 shares of the biotechnology company’s stock worth $3,712,000 after purchasing an additional 3,992 shares during the last quarter. Finally, BlackRock Inc. increased its position in Uniqure by 3.6% in the 3rd quarter. BlackRock Inc. now owns 481,106 shares of the biotechnology company’s stock valued at $17,507,000 after acquiring an additional 16,680 shares during the period. 60.16% of the stock is currently owned by institutional investors and hedge funds.
In other news, SVP Alexander Edward Kuta III sold 8,000 shares of Uniqure stock in a transaction on Friday, February 15th. The stock was sold at an average price of $35.82, for a total transaction of $286,560.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Christian Klemt sold 1,546 shares of Uniqure stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $57.18, for a total value of $88,400.28. Following the transaction, the insider now owns 54,539 shares in the company, valued at $3,118,540.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,922 shares of company stock worth $5,043,369. 1.56% of the stock is owned by insiders.
Several research firms recently commented on QURE. SunTrust Banks raised their target price on Uniqure to $76.00 and gave the company a “buy” rating in a research report on Tuesday. BidaskClub upgraded Uniqure from a “sell” rating to a “hold” rating in a research report on Tuesday. Piper Jaffray Companies began coverage on Uniqure in a research report on Friday, April 12th. They issued an “overweight” rating and a $80.00 target price on the stock. Robert W. Baird began coverage on Uniqure in a research report on Thursday, March 28th. They issued an “outperform” rating and a $85.00 target price on the stock. Finally, Wells Fargo & Co raised their target price on Uniqure from $65.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, March 15th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $75.82.
Shares of QURE stock opened at $58.75 on Thursday. Uniqure NV has a 1 year low of $21.98 and a 1 year high of $69.60. The firm has a market cap of $2.28 billion, a PE ratio of -25.11 and a beta of 0.99. The company has a debt-to-equity ratio of 0.38, a quick ratio of 9.51 and a current ratio of 9.51.
Uniqure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.03). Uniqure had a negative net margin of 1,032.06% and a negative return on equity of 48.90%. The firm had revenue of $1.14 million for the quarter, compared to analyst estimates of $2.00 million. As a group, research analysts expect that Uniqure NV will post -3.03 earnings per share for the current year.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Further Reading: Elliott Wave Theory
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.